Oncternal Therapeutics Stock Price. Everything You Need To Know About The Oncternal Therapeutics Stock!
Oncternal Therapeutics, Inc. is a San Diego-based biotechnology company focused on developing innovative oncology therapies to address unmet medical needs for patients with cancer. With a team of 30 full-time employees, the company is committed to advancing its product candidates, including Zilovertamab, ONCT-808, ONCT-534, and ONCT-216.
Zilovertamab, an investigational monoclonal antibody, targets Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor expressed on many tumors. By inhibiting ROR1, Zilovertamab may help to reduce tumor proliferation, invasiveness, and drug resistance.
ONCT-808, a chimeric antigen receptor (CAR-T) therapy, also targets ROR1 and is being developed for the treatment of hematologic malignancies and solid tumors.
ONCT-534, a dual-action androgen receptor inhibitor (DAARI), is being developed for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.
As a biotechnology company, Oncternal Therapeutics’ success hinges on its ability to develop effective oncology therapies. Keeping an eye on stocks share price today, premarket activity, and market cap can provide valuable insights into the company’s financial health and progress. It’s important to conduct thorough research and analysis before making any investment decisions, especially in the highly complex and dynamic field of biotechnology.
Oncternal Therapeutics Stock Price. Everything You Need To Know About The Oncternal Therapeutics Stock! performance
- Employees 30
- Company HQ San Diego
- Website http://www.oncternal.com/
- ONCT Asset Type Common Stock
- ONCT Market Capitalization 25.1M
- Earnings Per Share -13.43
- Dividends Per Share None
- Dividend Date 2019-06-10
- Quarterly Earnings Growth 0
Are you an investor from Malaysia, Thailand, Indonesia, or Vietnam looking to expand your investment portfolio and gain exposure to the US stock market? Look no further than Oncternal Therapeutics. As an emerging biotechnology company, Oncternal Therapeutics is focused on the development of innovative cancer treatments. With its cutting-edge research and a strong pipeline of potential therapies, investing in Oncternal Therapeutics can be a lucrative opportunity. At Zorion, we provide investment insights and recommendations to help retail investors like you make informed decisions about your investments. Our platform offers access to real US stocks and Pre-IPO companies, ensuring that you have a diverse range of investment options. Additionally, we provide educational resources and materials to expand your investment knowledge. Invest in Oncternal Therapeutics today and pave your way to financial success with Zorion.
